Gilead to Acquire Arcellx for $7.8 Billion
Gilead Sciences has announced its intention to acquire Arcellx in a deal valued at $7.8 billion, expanding its portfolio in the biotechnology sector.
Results for “Arcellx”
7 stories found
Gilead Sciences Acquires Arcellx for $7.8 Billion
Gilead Sciences has announced its acquisition of Arcellx in a deal valued at up to $7.8 billion.
Biotech and Pharmaceutical Companies Announce Clinical Milestones and Regulatory Updates
Multiple biotech and pharmaceutical companies, including Legend Biotech, Corcept Therapeutics, and Ultragenyx, have released updates on their drug pipelines, clinical trial data, and regulatory interactions, impacting market outlook.
Stocks making the biggest moves premarket: Arcellx, Novo Nordisk, Domino's Pizza and more
These are the stocks posting the largest moves in premarket trading.
Arcellx Sells $80 Million in Stock Following Steep Drop and Rival Drug Emergence
Arcellx has completed an $80 million stock sale, which comes after a significant drop in its stock price and the emergence of a rival drug in the market.
Gilead to Acquire Cancer Drug Developer Arcellx for Up to $7.8 Billion
Gilead Sciences announced its plan to acquire cancer drug developer Arcellx in a deal valued at up to $7.8 billion, as pharmaceutical groups continue to acquire smaller biotech firms.
Biotech Firm Arcellx Acquired for $26 Million Amid Stock Underperformance and Competition
Biotech company Arcellx has been sold for $26 million, following a period of weak stock performance and increasing competition from rivals like Kelonia.